Discover and read the best of Twitter Threads about #CtDNA
Most recents (15)
Excited to share our TRACERx nature publication on circulating tumor DNA (#ctDNA, #MRD) detection in resectable lung cancer led by @AbboshChris, @AFrankell, @juditkisistok, Thomas Harrison, Aaron Garnett, @nbirkbak and @NickyMcGranahan 👇👇👇 Tweetorial🧵
nature.com/articles/s4158…
nature.com/articles/s4158…
🔬Circulating tumor DNA is a powerful biomarker that can guide and monitor treatment response in early-stage lung cancer patients. Technologies enabling ctDNA detection and characterization are advancing rapidly but we need to understand how to use them in the clinic…
👥 Through collaboration with scientists at @TheCrick and @uclcancer, @AstraZeneca and @Invitae, we developed and validated an anchored-multiplex PCR approach ctDNA detection in 197 patients who donated over 1000 plasma samples to TRACERx.
@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @CCAlliance 1/22 #TumorBoardTuesday #ColonCancerAwarenessMonth #OncTwitter @shafiarahman_
62 yo 👨🏼🦳 asymptomatic
🔦 Screening colonoscopy - sigmoid mass
🔬Biopsy + for pMMR/MSS adenocarcinoma
🩻Staging CT + for unresectable liver mets
🤨What first line systemic treatment would you choose?
62 yo 👨🏼🦳 asymptomatic
🔦 Screening colonoscopy - sigmoid mass
🔬Biopsy + for pMMR/MSS adenocarcinoma
🩻Staging CT + for unresectable liver mets
🤨What first line systemic treatment would you choose?
@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @CCAlliance @shafiarahman_ 2/22 #TumorBoardTuesday @MPishvaian @JohnEbbenMDPhD #CRCAwarenessMonth
👨🏼🦳started on first line FOLFOX
🧪NGS testing
KRAS/BRAF WT
TMB low
ERBB2 negative
ATM mutation
👨🏼🦳started on first line FOLFOX
🧪NGS testing
KRAS/BRAF WT
TMB low
ERBB2 negative
ATM mutation
@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @CCAlliance @shafiarahman_ 3/22 #TumorBoardTuesday #GI23 #CRCAwareness
👩🏻🏫Mini tweetorial 1👨🏻🏫
↩️Left side tumors more common:
BRAF WT
KRAS WT
HER2 amp
↪️Right side tumors enriched for
BRAF V600E mutation
KRAS Mut
MSI-H
📚@ASCO
👩🏻🏫Mini tweetorial 1👨🏻🏫
↩️Left side tumors more common:
BRAF WT
KRAS WT
HER2 amp
↪️Right side tumors enriched for
BRAF V600E mutation
KRAS Mut
MSI-H
📚@ASCO
Great idea: time for Elacestrant thread Tuesday! 🧵
But first a reminder: access to paywalled papers from @Annals_Oncology, @ESMO_Open & multiple other affiliated journals is free for @myESMO members, and I could not recommend more to become a member! esmo.org/membership
1/
But first a reminder: access to paywalled papers from @Annals_Oncology, @ESMO_Open & multiple other affiliated journals is free for @myESMO members, and I could not recommend more to become a member! esmo.org/membership
1/
Endocrine treatment is among the most effective treatment strategies we have for breast cancer. 50 years ago, the approval of the SERD tamoxifen really revolutionized the field, & we still use the drug today.
Yet, no novel ET had been approved for the last 20 years. Until now
2/
Yet, no novel ET had been approved for the last 20 years. Until now
2/
Multiple oral SERDs (selective estrogen receptor degraders) are being developed for patients with HR+ MBC. The first to achieve positive phase 3 results was elacestrant, tested in the #EMERALD trial vs. SoC ET (fulvestrant or AI). Primary endpoint -> PFS overall & in ESR1-mut
3/
3/
Very excited to share our new study on determinants of resistance to anti-CD19 CAR T-cells (CART19) in large B-cell lymphomas (LBCLs)! Out today in @Cancer_Cell /1
cell.com/cancer-cell/fu…
cell.com/cancer-cell/fu…
A fantastic collaboration from @StanfordMed and @StanfordCancer led by Brian Sworder, David Kurtz, @StefanAlig, and Matthew Frank with David Miklos & @max_diehn to help improve outcomes following CAR T-cell therapy in lymphomas & beyond /2
We serially profiled plasma & tumor samples from 138 r/rLBCL patients across 2 independent cohorts treated w/ SOC axicabtagene ciloleucel (#axicel #yescarta) @StanfordBMT_CT /3
I would like to do my 2nd deep dive post #ASCO22 analysis on #ctDNA guided adjuvant therapy for pts with stage II colon cancer‼️
✳️The DYNAMIC trial is certainly step forward (kudos) ‼️But doesn’t answer many questions❗️@OncoAlert @manjuggm @CrcChange @TheColonClub Why ?👇
✳️The DYNAMIC trial is certainly step forward (kudos) ‼️But doesn’t answer many questions❗️@OncoAlert @manjuggm @CrcChange @TheColonClub Why ?👇
1️⃣ Firstly, the whole point of ctDNA is identification of MRD so to give RIGHT chemotherapy to RIGHT patients❗️
✳️Not only reduce adjuvant tx, but offer it to patients who may potentially miss that opportunity (such as offering folfox to a patient with ctDNA (+)T3N0 disease)❗️
✳️Not only reduce adjuvant tx, but offer it to patients who may potentially miss that opportunity (such as offering folfox to a patient with ctDNA (+)T3N0 disease)❗️
2️⃣The DYNAMIC suggests we get same DFS rate whether we use ctDNA or conventional risks for decision‼️
✳️Then one would rightfully wonder why to use ctDNA over conventional clinicopathological criteria if we get same outcomes anyway by using MORE oxaliplation❓just to reduce 5FU❓
✳️Then one would rightfully wonder why to use ctDNA over conventional clinicopathological criteria if we get same outcomes anyway by using MORE oxaliplation❓just to reduce 5FU❓
#ASCO22
✳️Happy to say there is great progress for patients with CRC‼️
@OncoAlert @ASCO @manjuggm @CrcChange‼️
Here is summary of some key studies 👇
✳️Happy to say there is great progress for patients with CRC‼️
@OncoAlert @ASCO @manjuggm @CrcChange‼️
Here is summary of some key studies 👇
1️⃣ Immune checkpoint inhibitor monothetapy with dostarlimab for MMR-D is certainly practice changing❗️
✳️Although long term outcomes are needed, no need to reinvent the wheel‼️
✳️ Once a deep response achieved in MMR-D CRC it is very durable even in metastatic setting ‼️
✳️Although long term outcomes are needed, no need to reinvent the wheel‼️
✳️ Once a deep response achieved in MMR-D CRC it is very durable even in metastatic setting ‼️
#ASCO22
✳️DYNAMIC trial results are highly exciting and glad to see field is moving forward !
✳️Very encouraging findings that we are in right pathway to use #ctDNA for adjuvant tx‼️
However there are important points that we need to address 👇@ASCO @OncoAlert @MoffittNews
✳️DYNAMIC trial results are highly exciting and glad to see field is moving forward !
✳️Very encouraging findings that we are in right pathway to use #ctDNA for adjuvant tx‼️
However there are important points that we need to address 👇@ASCO @OncoAlert @MoffittNews
✳️Firstly, I am categorically against putting T4 and T3 disease into same pocket (stage II is highly heterogeneous)❗️
✳️Risk of peritoneal recurrence for T4 and T3 is not same and not even close ‼️
✳️Peritoneal microscopic disease doesn’t shed CtDNA as much as liver MRD‼️
✳️Risk of peritoneal recurrence for T4 and T3 is not same and not even close ‼️
✳️Peritoneal microscopic disease doesn’t shed CtDNA as much as liver MRD‼️
✳️Moreover, control group was a bit vague in this study, conventional risk factors are used for ad therapy which can offer you different approaches ‼️
✳️Currently there is not consensus for high risk stage II in NCCN and options include observation vs FP alone or doublet ‼️
✳️Currently there is not consensus for high risk stage II in NCCN and options include observation vs FP alone or doublet ‼️
1/12 #TumorBoardTuesday #CCA
56y 🚭M w/ abd pain, 🚫🍻, 🚫Hx hepatitis
FHx - uncle (80) CRC, aunt (40) breast Ca
📷CT: 9cm liver mass with portal vein clot
🔦EGD/Colonoscopy unrevealing
🔬Bx: poorly diff adenoCa. pMMR, PD-L1 CPS 0%
Unresectable IHCC, PS 0, how would U Tx?
56y 🚭M w/ abd pain, 🚫🍻, 🚫Hx hepatitis
FHx - uncle (80) CRC, aunt (40) breast Ca
📷CT: 9cm liver mass with portal vein clot
🔦EGD/Colonoscopy unrevealing
🔬Bx: poorly diff adenoCa. pMMR, PD-L1 CPS 0%
Unresectable IHCC, PS 0, how would U Tx?
2/12 #TumorBoardTuesday
💊Tx with G/C for 4mo➡️SDz
✂️Still unresectable
But…G2✋🏽🦶🏽neuropathy
🩺Outside tumor board discussion suggested switching Tx.
Tumor NGS
👉ARID1A S745fs
🤔What would you choose for next Tx?
💊Tx with G/C for 4mo➡️SDz
✂️Still unresectable
But…G2✋🏽🦶🏽neuropathy
🩺Outside tumor board discussion suggested switching Tx.
Tumor NGS
👉ARID1A S745fs
🤔What would you choose for next Tx?
3/12 #TumorBoardTuesday Mini-Tweetorial 1 👨🏫
#BiliaryTractCancer @curecc @CCA_Alliance
➡️ Other 1L Tx's
✅Ph2 high ORR for GCN @rachnatshroff
pubmed.ncbi.nlm.nih.gov/30998813/
✅Ph3 SWOG 1815⌛️data
clinicaltrials.gov/ct2/show/NCT03…
✅TOPAZ-1: G/C+durva⬆️mOS, mPFS, RRvs. G/C
meetings.asco.org/abstracts-pres…
#BiliaryTractCancer @curecc @CCA_Alliance
➡️ Other 1L Tx's
✅Ph2 high ORR for GCN @rachnatshroff
pubmed.ncbi.nlm.nih.gov/30998813/
✅Ph3 SWOG 1815⌛️data
clinicaltrials.gov/ct2/show/NCT03…
✅TOPAZ-1: G/C+durva⬆️mOS, mPFS, RRvs. G/C
meetings.asco.org/abstracts-pres…
@MPishvaian @TumorBoardTues @SalemGIOncDoc @YJanjigianMD @DocCatenacci @rachnatshroff @gabe_a_brooks @sonbol_bassam @JoeChaoMD @JohnEbbenMDPhD 2/13 #TumorBoardTuesday
Starts on FLOT. C2 c/b😴, neutropenia, LFT ⬆️.
Unplanned CT with🙅🏼♂️👎response, hard to separate mass from liver capsule (not metastatic).
MDC feels risk of R1 resection, but resectable. MMR testing, complete PMS2 & MLH1 loss
Starts on FLOT. C2 c/b😴, neutropenia, LFT ⬆️.
Unplanned CT with🙅🏼♂️👎response, hard to separate mass from liver capsule (not metastatic).
MDC feels risk of R1 resection, but resectable. MMR testing, complete PMS2 & MLH1 loss
@MPishvaian @TumorBoardTues @SalemGIOncDoc @YJanjigianMD @DocCatenacci @rachnatshroff @gabe_a_brooks @sonbol_bassam @JoeChaoMD @JohnEbbenMDPhD @LFerri123 @MarkarSheraz @doctorC369
@MPishvaian @TumorBoardTues @SalemGIOncDoc @YJanjigianMD @DocCatenacci @rachnatshroff @gabe_a_brooks @sonbol_bassam @JoeChaoMD @JohnEbbenMDPhD 3/13 #TumorBoardTuesday Mini 🧑🎓 tweetorial 1⏲️
🧐 How common is dMMR in non-metastatic #GEA?
➡️ ~8% in pooled data from pIII periop and adjuvant trials
1. pubmed.ncbi.nlm.nih.gov/31513484/
2. pubmed.ncbi.nlm.nih.gov/28241187/
@FilippoPietran4 @JeeyunM @LizzySmyth1
🧐 How common is dMMR in non-metastatic #GEA?
➡️ ~8% in pooled data from pIII periop and adjuvant trials
1. pubmed.ncbi.nlm.nih.gov/31513484/
2. pubmed.ncbi.nlm.nih.gov/28241187/
@FilippoPietran4 @JeeyunM @LizzySmyth1
Pls join us in welcoming @JohnEbbenMDPhD to #TumorBoardTuesday!! 🎊
Dr Ebben is an onc fellow from WI, interested in🧬med & immunotherapy. He’ll also debate🧀curds & the best🍦custard in WI! He’ll be assisting with case wrap up🎀
We’re excited to have him!! #TBTFellow 1/17
Dr Ebben is an onc fellow from WI, interested in🧬med & immunotherapy. He’ll also debate🧀curds & the best🍦custard in WI! He’ll be assisting with case wrap up🎀
We’re excited to have him!! #TBTFellow 1/17
2/17 #TumorBoardTuesday Thursday Case🎀(08/24/21)
Bringing #ctDNA to bear to improve pts🙌🏽 @pashtoonkasi shows us how we can♻️ 🎯therapies to extend survival.
We go deep -🔬molecular biology➡️clinical trials➡️pt case.
👉🏽Don’t forget🆓#CME credit: bit.ly/3B9i6Wd
Bringing #ctDNA to bear to improve pts🙌🏽 @pashtoonkasi shows us how we can♻️ 🎯therapies to extend survival.
We go deep -🔬molecular biology➡️clinical trials➡️pt case.
👉🏽Don’t forget🆓#CME credit: bit.ly/3B9i6Wd
3/17 #TumorBoardTuesday Thursday Case🎀(08/24/21)
📚We captured as much of @pashtoonkasi's discussion as we could in this moment:
#ColorectalCancer #CRC #OncTwitter
twitter.com/i/events/14288…
📚We captured as much of @pashtoonkasi's discussion as we could in this moment:
#ColorectalCancer #CRC #OncTwitter
twitter.com/i/events/14288…
Welcome to #TumorBoardTuesday
Hello Everyone,
I’m Manju George, a stage 3b rectal cancer survivor
I was diagnosed in 2017 & I wasn’t yet 45 then
Are you excited to discuss #CtDNA testing?
Let's get started..
But first things 1st
Tell us about you
#PatientExperience #CRCSM
Hello Everyone,
I’m Manju George, a stage 3b rectal cancer survivor
I was diagnosed in 2017 & I wasn’t yet 45 then
Are you excited to discuss #CtDNA testing?
Let's get started..
But first things 1st
Tell us about you
#PatientExperience #CRCSM
My tumor
-In the upper rectum near the recto-sigmoid
Clean CAP CT scan & MRI pelvis
CEA 1.0 at dx
LAR sx 1st
Stage 3b rectal, MSS, BRAF WT
No chemo-RT
4 cycles of CAPOX
Clean scans at the end of treatment🎉🎉
What about you?
#TumorBoardTuesday #CRCSM #CtDNA #LiquidBiopsies
-In the upper rectum near the recto-sigmoid
Clean CAP CT scan & MRI pelvis
CEA 1.0 at dx
LAR sx 1st
Stage 3b rectal, MSS, BRAF WT
No chemo-RT
4 cycles of CAPOX
Clean scans at the end of treatment🎉🎉
What about you?
#TumorBoardTuesday #CRCSM #CtDNA #LiquidBiopsies
Survivorship--Different parts, very nice diagram from @CancerSurvSM
Great patient worksheet resource here--smhs.gwu.edu/cancercontrolt…
#TumorBoardTuesday #PatientExperience #CtDNA
Great patient worksheet resource here--smhs.gwu.edu/cancercontrolt…
#TumorBoardTuesday #PatientExperience #CtDNA
Delighted to share our new study nature.com/articles/s4158… introducing PhasED-Seq out today @NatureBiotech.
A fantastic collaboration from @StanfordMedicine led by Dave_Kurtz & Joanne Soo with @max_diehn to help transform #cancer interception & monitoring by improving #LiquidBiopsy #ctDNA detection of #MRD.
#GI21 time for another #Tweetorial🧵 on
#LiquidBiopsies
#CirculatingTumorDNA
#ctDNA
in a very 🎯 “Target-rich” disease
#Cholangiocarcinoma
#HPBCSM
~3️⃣0️⃣% actionable findings
Interestingly we found more #FGFR🧬 fusions on liquid🩸than tissue 🔬. #OncoAlert
@TempusLabs
#LiquidBiopsies
#CirculatingTumorDNA
#ctDNA
in a very 🎯 “Target-rich” disease
#Cholangiocarcinoma
#HPBCSM
~3️⃣0️⃣% actionable findings
Interestingly we found more #FGFR🧬 fusions on liquid🩸than tissue 🔬. #OncoAlert
@TempusLabs
🧵2️⃣ #GI21
#Cholangiocarcinoma is the poster child of actionable aberrations & truly a 🎯“Target-rich” disease.
We focused on %numbers for aberrations for which there’s either an ✅approved drug, guideline endorsement, #clinicaltrials or even off-label reports/cases.👇🏾
#Cholangiocarcinoma is the poster child of actionable aberrations & truly a 🎯“Target-rich” disease.
We focused on %numbers for aberrations for which there’s either an ✅approved drug, guideline endorsement, #clinicaltrials or even off-label reports/cases.👇🏾
🧵3️⃣ #GI21
We often don’t think of #ctDNA based platforms to be as sensitive for detecting fusions; when present it is real & an actionable finding.
Interestingly we found #FGFR🧬fusions
🩸LIQUID>>TISSUE🔬
💭 maybe because of selection bias. #ctDNA filling the void. #OncoAlert
We often don’t think of #ctDNA based platforms to be as sensitive for detecting fusions; when present it is real & an actionable finding.
Interestingly we found #FGFR🧬fusions
🩸LIQUID>>TISSUE🔬
💭 maybe because of selection bias. #ctDNA filling the void. #OncoAlert
JPM Healthcare Daily Roundup #JPM2021
The first day of the conference hasn't disappointed, especially if you're a fan of talking cubes. What is this mysterious object and what sorcery is inside?
See disclosures at the end.
The first day of the conference hasn't disappointed, especially if you're a fan of talking cubes. What is this mysterious object and what sorcery is inside?
See disclosures at the end.
The Tempus One, meant to be carried in a doctor's coat or sat at the bedside, is a physical manifestation of @TempusLabs' genomic and phenotypic data-lake. Oncologists can ask One all sorts of questions regarding their patients, though I'm unsure if it'll (...)
(...) just reflex you to a computer after a sufficiently difficult question. I'm sure we'll learn more soon. Has this sort of form-factor been tried before?
I'm just hoping it has adjustable humor/honesty settings like TARS from Interstellar.
Moving right along.
I'm just hoping it has adjustable humor/honesty settings like TARS from Interstellar.
Moving right along.
Bird’s-eye view 👁 on what to look out for @WCGIC #WorldGI2020.
Opening remarks on important data 📺 @myESMO - by Dr. Eric Van Cutsem @UZLeuven.
🟩Good to see more #PrecisionMedicine🧬
🟥#Immunotherapy #Immuno-#oncology
🟦TNT & other chemo strategies
@Annals_Oncology #OncoAlert
Opening remarks on important data 📺 @myESMO - by Dr. Eric Van Cutsem @UZLeuven.
🟩Good to see more #PrecisionMedicine🧬
🟥#Immunotherapy #Immuno-#oncology
🟦TNT & other chemo strategies
@Annals_Oncology #OncoAlert
🆕#ctDNA #liquidbiopsies 🩸🧬
👀 👇🏾at the number of #clinicaltrials cropping up in this space‼️
🇦🇺DYNAMIC-II
🇦🇺DYNAMIC-III
🇺🇸COBRA @NRGonc
🇺🇸BESPOKE
🇺🇸@SU2C
🇯🇵 CIRCULATE
🌎COLUMBIA
🇮🇹🇪🇸PEGASYS
🇬🇧TRACC
🇩🇪CIRCULATE
🇫🇷crEATE
🇩🇰IMPROVE-IT
We have 2🇺🇸studies open. #CRCSM #WorldGI2020
👀 👇🏾at the number of #clinicaltrials cropping up in this space‼️
🇦🇺DYNAMIC-II
🇦🇺DYNAMIC-III
🇺🇸COBRA @NRGonc
🇺🇸BESPOKE
🇺🇸@SU2C
🇯🇵 CIRCULATE
🌎COLUMBIA
🇮🇹🇪🇸PEGASYS
🇬🇧TRACC
🇩🇪CIRCULATE
🇫🇷crEATE
🇩🇰IMPROVE-IT
We have 2🇺🇸studies open. #CRCSM #WorldGI2020
#WORLDGI2020 This is 🆒 ☢️ 32-P EUS-guided implantation in #pancreascancer #PANCSM @myESMO @WCGIC @Annals_Oncology.
Still miles to go. OS median of 16 months pointing again to the systemic nature of disease. Need to piggyback these local approaches to better systemic. #OncoAlert
Still miles to go. OS median of 16 months pointing again to the systemic nature of disease. Need to piggyback these local approaches to better systemic. #OncoAlert
